Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $35,840.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Rating) insider Tia L. Bush sold 8,000 shares of Centessa Pharmaceuticals stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $4.48, for a total value of $35,840.00. Following the transaction, the insider now directly owns 157,102 shares of the company’s stock, valued at $703,816.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Centessa Pharmaceuticals Trading Up 0.7 %

Shares of Centessa Pharmaceuticals stock traded up $0.03 during trading on Friday, hitting $4.32. 23,840 shares of the company were exchanged, compared to its average volume of 166,237. The firm has a market capitalization of $410.84 million, a P/E ratio of -1.94 and a beta of 0.86. Centessa Pharmaceuticals plc has a 1-year low of $2.88 and a 1-year high of $6.09. The firm’s fifty day moving average price is $4.28 and its 200 day moving average price is $3.83. The company has a debt-to-equity ratio of 0.24, a current ratio of 12.95 and a quick ratio of 12.95.

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) last released its quarterly earnings data on Thursday, March 30th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.03. As a group, sell-side analysts expect that Centessa Pharmaceuticals plc will post -1.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. SVB Securities assumed coverage on Centessa Pharmaceuticals in a research note on Friday, March 17th. They issued an “outperform” rating and a $6.00 target price for the company. SVB Leerink restated an “outperform” rating and issued a $6.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $5.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Barclays PLC bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at about $25,000. JPMorgan Chase & Co. lifted its stake in Centessa Pharmaceuticals by 275.9% in the 4th quarter. JPMorgan Chase & Co. now owns 12,747 shares of the company’s stock valued at $39,000 after acquiring an additional 9,356 shares in the last quarter. Susquehanna International Group LLP bought a new stake in Centessa Pharmaceuticals in the 1st quarter valued at approximately $49,000. Renaissance Technologies LLC bought a new stake in Centessa Pharmaceuticals in the 1st quarter valued at approximately $60,000. Finally, Goldman Sachs Group Inc. bought a new stake in Centessa Pharmaceuticals in the 2nd quarter valued at approximately $81,000. Institutional investors own 78.03% of the company’s stock.

About Centessa Pharmaceuticals

(Get Rating)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.